JPMorgan raises target to USD 55 for Qiagen stock

Published on 10/15/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan lifted its target from USD 50 to USD 55 on October 14, 2026. Qiagen stock costs EUR 41.18 on October 15, 2026 in Germany.

Target and earnings context

JPMorgan raised its Qiagen target from USD 50 to USD 55 on October 14, 2026.
Second-quarter revenue reached USD 535.04 million against USD 527.50 million expected.
Qiagen stock was trading at EUR 41.18 at 10:00 a.m. CEST at Lang & Schwarz on October 15, 2026.
The Global TB Clinical and Educational Summit runs through October 16, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) was trading at EUR 41.18 at Lang & Schwarz at 10:00 a.m. CEST on October 15, 2026. The immediate catalyst was JPMorgan's decision on October 14, 2026, to raise its price target from USD 50 to USD 55 while keeping an Overweight rating, as Markets Insider reported.

Why the target moved higher

The JPMorgan update was framed as part of a third-quarter earnings preview for life-science tools and diagnostics. The new USD 55 target is USD 5 above the former level, a 10.00 percent increase in the stated target.

Qiagen's latest reported operating figures provide the numerical backdrop. In the second quarter of 2026, revenue was USD 535.04 million, compared with USD 527.50 million expected, while reported earnings per share reached USD 0.62 against a USD 0.60 consensus, according to MarketBeat.

What does the valuation imply?

The target change points to a more constructive view of Qiagen's growth execution, but the broader rating picture is less uniform. MarketBeat reported a consensus target of USD 43.93 and an average Hold rating, leaving JPMorgan's USD 55 view above that consensus.

Three dated developments

On August 5, 2026, Qiagen reported second-quarter revenue of USD 535.04 million and earnings per share of USD 0.62, according to MarketBeat. On October 7, 2026, Qiagen introduced two bioinformatics platforms, according to The Fly. On October 14, 2026, JPMorgan raised the target to USD 55 from USD 50, as Markets Insider reported.

Upcoming dates for Qiagen

Qiagen's Global TB Clinical and Educational Summit is scheduled from October 13 through October 16, 2026, with the company presenting its tuberculosis focus during the event, according to MarketScreener. The date gives investors a near-term company event alongside the earnings preview.

Stock trades in the German session

Qiagen operates in healthcare and medical diagnostics, serving more than 500,000 customers, according to its investor-relations overview. Its primary U.S. listing is on the NYSE under QGEN, while the German quotation provides the euro perspective used here.

Qiagen was trading at EUR 41.18 at Lang & Schwarz on October 15, 2026 at 10:00 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.